<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.133812.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Comparison of vitreous/retinal pigment epithelium relative intensity in proliferative vitreoretinopathy and uveitis &#x202f;</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 2 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Djatikusumo</surname>
                        <given-names>Ari</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Funding Acquisition</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-8530-3374</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Victor</surname>
                        <given-names>Andi Arus</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-8618-1468</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Harahap</surname>
                        <given-names>Alida Roswita</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Wibowo</surname>
                        <given-names>Heri</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>LDR Nora</surname>
                        <given-names>Rina</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Setiabudy</surname>
                        <given-names>Rianto</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a5">5</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Sovani</surname>
                        <given-names>Iwan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a6">6</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Edwar</surname>
                        <given-names>Lukman</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-5484-9515</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Permadi</surname>
                        <given-names>Annisa Citra</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-9385-4264</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Ardhia</surname>
                        <given-names>Seruni Hanna</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a7">7</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia</aff>
                <aff id="a2">
                    <label>2</label>Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia &#x2014; Cipto Mangunkusumo Kirana Eye Hospital, Jakarta, Indonesia</aff>
                <aff id="a3">
                    <label>3</label>Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia</aff>
                <aff id="a4">
                    <label>4</label>Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia</aff>
                <aff id="a5">
                    <label>5</label>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia</aff>
                <aff id="a6">
                    <label>6</label>Department of Ophthalmology, Faculty of Medicine, Universitas Padjajaran &#x2014; Cicendo National Eye Hospital, Bandung, Indonesia</aff>
                <aff id="a7">
                    <label>7</label>Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:lukmanedwar@gmail.com">lukmanedwar@gmail.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>10</day>
                <month>7</month>
                <year>2023</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2023</year>
            </pub-date>
            <volume>12</volume>
            <elocation-id>807</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>4</day>
                    <month>5</month>
                    <year>2023</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Djatikusumo A et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/12-807/pdf"/>
            <abstract>
                <p>
                    <bold>Background:</bold> Quantitative measurements of vitreous inflammation using vitreous/retinal pigment epithelium-relative intensity (VIT/RPE-Relative Intensity) have been described recently. In proliferative vitreoretinopathy (PVR), inflammation plays a central role in the pathogenesis, inducing retinal fibrosis and contraction. However, no attempts have yet to be made to analyze the severity of inflammation in PVR progression.</p>
                <p>
                    <bold>Methods:</bold> A cross-sectional study was conducted by reviewing OCT image sets obtained from patients divided into four groups: (1) proliferative vitreoretinopathy, (2) intermediate and posterior uveitis, (3) panuveitis, (4) normal healthy eyes in Cipto Mangunkusumo Kirana Eye Hospital between April 2021 &#x2013; December 2021. OCT images were then analyzed in the ImageJ software for VIT/RPE-relative intensity.</p>
                <p>
                    <bold>Results:</bold> A total of 19 PVR eyes, 12 intermediate-posterior uveitis eyes, 16 panuveitis eyes, and 28 normal healthy eyes were recruited for this study. The VIT/RPE-Relative Intensity was significantly higher in PVR eyes (0.415&#x00b1;0.178) than in intermediate-posterior uveitis (0.236&#x00b1;0.043, p=0.002) and panuveitis eyes (0.30&#x00b1;0.07, p=0.023). Compared to the normal eyes, PVR and both uveitis groups have significantly higher VIT/RPE relative intensity (p = &lt;0.001 in each group).</p>
                <p>
                    <bold>Conclusions:</bold> VIT/RPE-relative intensity may offer quantitative measurements of vitreous inflammation in the role of the pathogenesis of PVR. Comparison with cellular inflammation in the vitreous is required to validate this finding.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Vitreous/Retinal Pigment Epithelium-Relative Intensity</kwd>
                <kwd>Proliferative Vitreoretinopathy</kwd>
                <kwd>Uveitis</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>Rhegmatogenous retinal detachment (RRD) can produce some degree of vitreous haziness that may be associated with its severity and prognosis.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> RRD causes neurosensory retina and retinal pigment epithelium (RPE) separation, which leads to retinal ischemia and blood-retinal barrier disruption.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> These two events serve as initiating inflammatory factors of the pathogenesis of proliferative vitreoretinopathy (PVR).
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> Exposure of RPE cells to the vitreous results in the migration of cytokines, inflammatory cells, and growth factors into the vitreous cavity to further stimulate cellular responses that lead to a turbid vitreous. Inflammation plays a central role in stimulating the development of epiretinal membranes and retinal fibrosis, latter findings in PVR.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup>
            </p>
            <p>According to the updated Retina Society Classification, PVR is classified into grades; A, B, and C. Grade A is defined as the presence of vitreous haziness and pigment clumping. Grade B is defined as surface retinal wrinkle, rolled edges of retinal breaks, retinal stiffness, and artery-venous tortuosity; and grade C is full-thickness retinal folds and/or subretinal bands.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> However, most clinicians use this classification only as prognostic hints and a guideline in which vitreous substitute is used, i.e. gas or silicone oil. It does not address the role of inflammation that generates during RRD development. Vitreous haze caused by inflammation is not specific to PVR, as it can also be present in uveitis or a retinal detachment without PVR.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> Furthermore, this classification does not offer any information regarding the severity of inflammation, which plays an essential role in the pathogenesis and disease severity in PVR.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup>
            </p>
            <p>Optical coherence tomography (OCT) is a non-invasive diagnostic procedure that provides cross-sectional images of ocular tissue, allowing qualitative assessment of retinal diseases and automated retinal thickness measurements. Recently, OCT has been described to visualize vitreous haziness in patients with uveitis
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup> Quantitative measurements of vitreous haze or inflammation using OCT images were obtained by measuring the vitreous intensity relative to retinal pigmented epithelium intensity, which is termed VIT/RPE-relative intensity. Studies have reported that the VIT/RPE relative intensity is significantly higher in uveitis eyes than in eyes without vitreous haze; furthermore, validation analysis shows a positive correlation with Nussenblatt vitreous haze scale.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup>
            </p>
            <p>This study aims to objectively measure vitreous haziness in PVR compared to uveitis and normal eyes by measuring vitreous intensity relative to retinal pigment epithelium intensity captured through OCT.</p>
        </sec>
        <sec id="sec2" sec-type="methods">
            <title>Methods</title>
            <sec id="sec3">
                <title>Study design</title>
                <p>We obtained OCT image sets from four groups of consecutive patients in Cipto Mangunkusumo Kirana Eye Hospital between April 2021 and December 2021.</p>
            </sec>
            <sec id="sec4">
                <title>Sample</title>
                <p>The participants were identified during their visit to Cipto Mangunkusumo Kirana Eye Hospital. Those who met the inclusion criteria and provided informed consent were included. The procedures were done during routine appointments.</p>
                <p>The first group of data included images from eyes with RRD and PVR. The inclusion criteria for the RRD and PVR group were patients with macula-off RRD and PVR with grade A or B, age of 18 or above, and RRD onset upon examination of 7 days to 1 month. The exclusion criteria of the RRD and PVR group were patients with media opacification (i.e., cataracts, vitreous hemorrhage), a history of intraocular surgery in less than 3 months, and patients with other eye disease comorbidities (i.e., macular hole, age-related macular degeneration, intraocular tumor).</p>
                <p>The second and third groups were obtained from uveitis patients, which were divided into two groups; (1) intermediate and posterior uveitis; (2) panuveitis. We excluded uveitis patients with vitreous hemorrhage, retinal pigment epithelial irregularity such as in age-related macular degeneration, intraocular tumor, and choroidal neovascularization, history of triamcinolone acetate intravitreal within 6 months, and vitrectomized eyes.</p>
                <p>The fourth group was the control group, which included image sets from normal eyes that did not show signs of intraocular inflammation or any ocular disease. We only include patients in each group with goodand readable OCT imaging quality, defined as clear visualization of the vitreous cavity, neurosensory layer, and RPE layer in one OCT image.</p>
                <p>The estimation sample size for the present study was calculated using correlation coefficient (r) based on the previous study of Keane 
                    <italic toggle="yes">et al.</italic>
                    <sup>
                        <xref ref-type="bibr" rid="ref10">10</xref>
                    </sup> (r=0.566). By implementing this method, the sample size would be 29 for the uveitis group. The sample size for the PVR and control group will be adjusted with the uveitis group.</p>
            </sec>
            <sec id="sec5">
                <title>Ethical considerations</title>
                <p>This study was conducted based on the Declaration of Helsinki and was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia and Cipto Mangunkusumo Hospital (KET-87/UN2.F1/ETIK/PPM.00.02/2021) on 8
                    <sup>th</sup> February 2021. All subjects provided written informed consent.
                    <sup>
                        <xref ref-type="bibr" rid="ref21">21</xref>
                    </sup>
                </p>
            </sec>
            <sec id="sec6">
                <title>Procedure</title>
                <p>All participants underwent a complete ocular examination. Clinical data collected from each patient during recruitment and examination include age, sex, and best-corrected visual acuity (BCVA) using Snellen chart and converted into LogMAR. Etiology of uveitis patient was obtained from further work-ups. OCT Image was obtained by OCT Cirrus HD 4000 (Carl Zeiss Meditec, Dublin, CA) with HD-line raster scan protocol system in grayscale. This system has a 27,000 A-scans per second imaging speed and an axial resolution of 3.9 mm. Volume scans were centered on the fovea in each OCT image. The OCT images were taken by experienced staff nurses. Each patient will have 4 to 5 images taken until the best image is obtained.</p>
                <p>VIT/RPE Relative Intensity was measured with 
                    <ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">ImageJ</ext-link> software version 1.53 (National Institutes of Health, Bethesda, MD, USA). The image was manually segmented by a polygonal selection tool. OCT images were measured independently by two graders (ASA and FI). The value that will be included in the correlation analysis is the highest value of VIT/RPE-Relative Intensity obtained from the measurements. All images were randomized and the OCT image graders were masked from patient data and diagnosis to reduce the risk of bias.</p>
            </sec>
            <sec id="sec7">
                <title>Quantitative measurements of the vitreous Inflammation using ImageJ</title>
                <p>OCT images were obtained from OCT and imported into free access software ImageJ. This software enables manual segmentation and measurements of OCT images for the intensity of the vitreous and retinal pigment epithelium area. We measured vitreous inflammation or hazziness using the Vitreous/RPE Relative Intensity. Images were set to 8-bit type before measurement. The boundaries definition for measurements was based on the previous study by Keane 
                    <italic toggle="yes">et al</italic>.
                    <sup>
                        <xref ref-type="bibr" rid="ref10">10</xref>
                    </sup> Boundaries of the vitreous area consist of (1) &#x201c;vitreous top&#x201d;, the upper limit of the vitreous area visible in OCT; (2) internal limiting membrane (ILM), the inner border of the neurosensory retina. Vitreous absolute intensity is defined as the intensity of the vitreous area, which is the area between the vitreous top and internal limiting membrane. Boundaries for the RPE area consisted of (1) inner-retinal pigment epithelium (RPE), the inner border of RPE; and (2) outer-RPE, the outer boundary of the RPE. The RPE intensity is described as the space between the RPE&#x2019;s inner and outer boundaries.</p>
            </sec>
            <sec id="sec8">
                <title>Statistical analysis</title>
                <p>Clinical and imaging data were analyzed using descriptive statistics. T-independent test was used for the VIT/RPE relative intensity mean value between groups. P values&lt;0.05 were considered statistically significant. All analyses were performed using 
                    <ext-link ext-link-type="uri" xlink:href="https://www.ibm.com/products/spss-statistics">IBM SPSS</ext-link>, version 26 (IBM Corp), and 
                    <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/features">GraphPad Prism</ext-link> 9.0 (GraphPad Software, Inc., San Diego, CA).</p>
            </sec>
        </sec>
        <sec id="sec9" sec-type="results">
            <title>Results</title>
            <p>A total of 29 eyes in the uveitis group and 37 eyes in the RRD-PVR group were eligible for the study.
                <sup>
                    <xref ref-type="bibr" rid="ref19">19</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref20">20</xref>
                </sup> However, there were only 28 eyes in the uveitis group and 19 eyes in the RRD-PVR group that met the criteria of good and readable OCT. A finaltotal of 19 PVR eyes, 28 uveitis eyes (12 intermediate-posterior uveitis eyes and 16 panuveitis eyes), and 28 normal healthy eyes were recruited for this study. The mean age of patients was 43&#x00b1;11.95 years in the PVR group with 63.16% male patients. In the intermediate-posterior uveitis group, the mean age was 36.58&#x00b1;12.17 years with an equal of six male and female patients, and in the panuveitis group, the mean age was 34.75&#x00b1;10.88 years with 62.5% female patients. Visual acuity in the three groups ranged between 0 to 2.5 LogMAR units. The clinical characteristics of each group are described in 
                <xref ref-type="table" rid="T1">Table 1</xref>.</p>
            <table-wrap id="T1" orientation="portrait" position="float">
                <label>Table 1. </label>
                <caption>
                    <title>Baseline characteristics of PVR, uveitis, and control subjects.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Characteristic</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">PVR (n=19)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Uveitis (n=12)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Panuveitis (n=16)</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Normal (n=28)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Age (years)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">43(&#x00b1;11.95)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">36.58(&#x00b1;12.17)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">34.75(&#x00b1;10.88)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">29.07(&#x00b1;1.41)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Gender</td>
                            <td colspan="1" rowspan="1"/>
                            <td colspan="1" rowspan="1"/>
                            <td colspan="1" rowspan="1"/>
                            <td colspan="1" rowspan="1"/>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Male</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">12(63.16%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">6(50%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">6(37.5%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">6(21.4%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Female</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">7(36.84%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">6(50%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">10(62.5%)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">22(78.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">BCVA (LogMAR)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">0.67(0-2.5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">0.67(0-2.5)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">1.08(&#x00b1;0.62)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">0.0</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>BCVA: Best-Corrected Visual Acuity.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>Characteristics of patients in the rhegmatogenous retinal detachments and proliferative vitreoretinopathy group are described in 
                <xref ref-type="table" rid="T2">Table 2</xref>. RRD duration upon examination was mostly 0-7 days (52.6%). All patients included in the study were PVR grade B.</p>
            <table-wrap id="T2" orientation="portrait" position="float">
                <label>Table 2. </label>
                <caption>
                    <title>Characteristics of Rhegmatogenous Retinal Detachment (RRD) patients.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Characteristics</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">RRD (n=19)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Duration (days)</td>
                            <td colspan="1" rowspan="1"/>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;0-7</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">10(52.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;8-30</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">9(47.4%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">PVR Grade</td>
                            <td colspan="1" rowspan="1"/>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;A</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">0(0%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;B</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">19(100%)</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>PVR: Proliferative vitreoretinopathy.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>From 28 uveitis patients that were included in the study, the most common etiologies were toxoplasma (28.6%) and sifilis (25%). The characteristics of uveitis patients were summarized in 
                <xref ref-type="table" rid="T3">Table 3</xref>.</p>
            <table-wrap id="T3" orientation="portrait" position="float">
                <label>Table 3. </label>
                <caption>
                    <title>Characteristics of Uveitis patients.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Characteristics</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Uveitis (n=28)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Location</td>
                            <td colspan="1" rowspan="1"/>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Intermediate + Posterior</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">12(41.4%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Panuveitis</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">16(58.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Etiology</td>
                            <td colspan="1" rowspan="1"/>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Toxoplasma</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">8(28.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Sifilis</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">7(25%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;CMV</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">1(3.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;VKH</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">1(3.6%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Tuberculosis</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">6(21.4%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Paraneoplastic syndrome</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">2(7.14%)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">&#x2003;Idiopathic</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">3(10.7%)</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>CMV: Cytomegalovirus; VKH: Vogt-Koyanagi Harada Disease.</p>
                </table-wrap-foot>
            </table-wrap>
            <p>The VIT/RPE-Relative Intensity of each group (&#x201c;proliferative vitreoretinopathy&#x201d;, &#x201c;intermediate-posterior uveitis&#x201d;, &#x201c;panuveitis&#x201d;, and &#x201c;normal eyes&#x201d;) are described in 
                <xref ref-type="fig" rid="f1">Figure 1</xref>. The VIT/RPE-Relative Intensity index in the PVR eyes (0.415&#x00b1;0.178) was found to be significantly higher in PVR than in intermediate-posterior uveitis (0.236&#x00b1;0.043) (p=0.002) and in panuveitis eyes (0.30&#x00b1;0.07) (p=0.023). A significant difference was also found between the intermediate-posterior uveitis and panuveitis groups (p=0.008). Compared to the healthy controls, PVR and both uveitis groups have significantly higher VIT/RPE relative intensity (p&#x2264;0.001 in each group).</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>Figure 1. </label>
                <caption>
                    <title>The mean difference of VIT/RPE-Relative Intensity (VRI) of PVR, Uveitis (Int-Post=intermediate-posterior), pan (panuveitis), and normal eyes.</title>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/146826/33e1de50-cd7c-4621-9ee0-d2a425f28631_figure1.gif"/>
            </fig>
        </sec>
        <sec id="sec10" sec-type="discussion">
            <title>Discussion</title>
            <p>Vitreous haze is defined as the accumulation of inflammatory cells and protein exudate in the vitreous cavity, resulting in the decreased visibility of the retina and optic nerve. In uveitis, vitreous haziness is one of the important clinical outcomes in disease evaluation.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref13">13</xref>
                </sup> OCT imaging enables direct visualization of vitreous haze.
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup> Recent studies have developed an objective, quantitative measurement of vitreous signal intensity, compared to RPE-absolute intensity. VIT/RPE-Relative Intensity is used to acquire quantitative measurements of vitreous haze in uveitis eyes, as studies reported to be significantly higher compared with normal eyes.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>
            </p>
            <p>Previous studies reported increased levels of cytokines, growth factors, and inflammatory cells in the vitreous of RRD-PVR eyes, including macrophages, transforming growth factor-&#x03b2; (TGF-&#x03b2;), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-&#x03b1;), interleukin (IL)-6 and IL-8.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref15">15</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref18">18</xref>
                </sup> These inflammatory cells, pro-inflammatory cytokines, and growth factors facilitate RPE cell migration, proliferation, and epithelial-mesenchymal transition, which leads to the development of retinal fibrosis and contraction.
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup>
            </p>
            <p>Our study showed that VIT/RPE-Relative Intensity in the PVR group is significantly higher than intermediate-posterior uveitis, panuveitis, and normal eyes. We also compared intermediate-posterior uveitis with panuveitis, with the result of the value of VIT/RPE Relative Intensity in the panuveitis group being significantly higher than the intermediate-posterior uveitis (p=0.008). Both uveitis groups also are significantly higher compared to normal eyes. These results may indicate that the inflammation and protein exudate into the vitreous cavity of PVR is higher than in uveitis cases. This study also showed similar findings for the VIT/RPE-Relative Intensity of uveitis eyes described in previous studies.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup>
            </p>
            <p>These results are a preliminary finding in validating the VIT/RPE-Relative Intensity use for measuring vitreous inflammation objectively in the role of the pathogenesis of PVR and may be useful to obtain a new standard classification of PVR that corresponds to the inflammatory status of the disease. The higher value of VIT/RPE-Relative Intensity in PVR than in uveitis may indicate the need for anti-inflammatory drug use in PVR, in addition to surgery, to decrease disease severity.</p>
            <p>We understand that this study had some limitations regarding the subject number, with only 19 subjects in the PVR group. A larger study comparing the VIT/RPE-Relative Intensity index and vitreous inflammatory cells, cytokines, and growth factors in PVR patients will be required to validate our significant findings.</p>
        </sec>
    </body>
    <back>
        <sec id="sec13" sec-type="data-availability">
            <title>Data availability</title>
            <sec id="sec14">
                <title>Underlying data</title>
                <p>Figshare: Comparison of Vitreous/Retinal Pigment Epithelium Relative Intensity in Proliferative Vitreoretinopathy and Uveitis. 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.22632715.v1">https://doi.org/10.6084/m9.figshare.22632715.v1</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref19">19</xref>
</sup>

                    <list list-type="bullet">
                        <list-item>
                            <label>&#x2022;</label>
                            <p>Characteristics of Proliferative Vitreoretinopathy, Uveitis, and Normal Patients
</p>
                        </list-item>
                    </list>
                </p>
                <p>Mendeley Data: OCT images of Proliferative Vitreoretinopathy, Intermediate+Posterior Uveitis, Panuveitis, and Normal Eyes. 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17632/hbr5pwk5w5.1">https://doi.org/10.17632/hbr5pwk5w5.1</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref20">20</xref>
</sup>
                    <list list-type="bullet">
                        <list-item>
                            <label>&#x2022;</label>
                            <p>OCT images of Proliferative Vitreoretinopathy, Intermediate+Posterior Uveitis, Panuveitis, and Normal Eyes</p>
                        </list-item>
                    </list>
                </p>
            </sec>
            <sec id="sec15">
                <title>Extended data</title>
                <p>Figshare: Informed Consent &#x2013; Comparison of VIT/RPE-Relative Intensity in PVR and Uveitis (Translated to English). 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.22707988.v1">https://doi.org/10.6084/m9.figshare.22707988.v1</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref21">21</xref>
</sup>

                    <list list-type="bullet">
                        <list-item>
                            <label>&#x2022;</label>
                            <p>Informed Consent &#x2013; Comparison of VIT/RPE-Relative Intensity in PVR and Uveitis (Translated to English)
</p>
                        </list-item>
                    </list>
                </p>
                <p>Data are available under the terms of the 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link> (CC-BY 4.0).</p>
            </sec>
        </sec>
        <ack>
            <title>Acknowledgments</title>
            <p>The authors wish to thank all healthcare providers in the Faculty of Medicine &#x2013; Cipto Mangunkusumo Kirana Eye Hospital that was involved in the completion of the study.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ni</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Qin</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Huang</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy.</article-title>
                    <source>

                        <italic toggle="yes">Adv. Ther.</italic>
</source>
                    <year>2020</year>;<volume>37</volume>(<issue>5</issue>):<fpage>2550</fpage>&#x2013;<lpage>2559</lpage>.
                    <pub-id pub-id-type="pmid">32274748</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s12325020-01325-x</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7467460</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Machemer</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Aaberg</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Freeman</surname>
                            <given-names>HM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>An Updated Classification of Retinal Detachment with Proliferative Vitreoretinopathy.</article-title>
                    <source>

                        <italic toggle="yes">Am J. Ophthalmol.</italic>
</source>
                    <year>1991</year>;<volume>112</volume>(<issue>2</issue>):<fpage>159</fpage>&#x2013;<lpage>165</lpage>.
                    <pub-id pub-id-type="pmid">1867299</pub-id>
                    <pub-id pub-id-type="doi">10.1016/s0002-9394(14)76695-4</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Murakami</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Notomi</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hisatomi</surname>
                            <given-names>T</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Photoreceptor cell death and rescue in retinal detachment and degenerations.</article-title>
                    <source>

                        <italic toggle="yes">Prog. Retin. Eye Res.</italic>
</source>
                    <year>2013</year>;<volume>37</volume>:<fpage>114</fpage>&#x2013;<lpage>140</lpage>.
                    <pub-id pub-id-type="pmid">23994436</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.preteyeres.2013.08.001</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3871865</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chidlow</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chan</surname>
                            <given-names>WO</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wood</surname>
                            <given-names>JPM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Investigations into photoreceptor energy metabolism during experimental retinal detachment.</article-title>
                    <source>

                        <italic toggle="yes">Front. Cell. Neurosci.</italic>
</source>
                    <year>2022</year>;<volume>16</volume>(<issue>November</issue>):<fpage>1</fpage>&#x2013;<lpage>25</lpage>.
                    <pub-id pub-id-type="doi">10.3389/fncel.2022.1036834</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pastor</surname>
                            <given-names>JC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rojas</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pastor-Idoate</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences.</article-title>
                    <source>

                        <italic toggle="yes">Prog. Retin. Eye Res.</italic>
</source>
                    <year>2016 Mar</year>;<volume>51</volume>:<fpage>125</fpage>&#x2013;<lpage>155</lpage>.
                    <pub-id pub-id-type="pmid">26209346</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.preteyeres.2015.07.005</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Dai</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dai</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sun</surname>
                            <given-names>T</given-names>
                        </name>
</person-group>:
                    <article-title>Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review.</article-title>
                    <source>

                        <italic toggle="yes">Int. Ophthalmol.</italic>
</source>
                    <year>2020</year>;<volume>40</volume>:<fpage>1587</fpage>&#x2013;<lpage>1601</lpage>.
                    <pub-id pub-id-type="pmid">32103371</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s10792-020-01325-4</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7242233</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab>:
                    <article-title>Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Ophthalmol.</italic>
</source>
                    <year>2005</year>;<volume>140</volume>:<fpage>509</fpage>&#x2013;<lpage>516</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2005.03.057</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hoog</surname>
                            <given-names>JD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Berge</surname>
                            <given-names>JCT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Groen</surname>
                            <given-names>F</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Rhegmatogenous retinal detachment in uveitis.</article-title>
                    <source>

                        <italic toggle="yes">J. Ophthal. Inflamm. Infect.</italic>
</source>
                    <year>2017</year>;<volume>7</volume>(<issue>22</issue>):<fpage>22</fpage>.
                    <pub-id pub-id-type="pmid">29164419</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s12348-017-0140-5</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5698237</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Di Lauro</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kadhim</surname>
                            <given-names>MR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Charteris</surname>
                            <given-names>DG</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years.</article-title>
                    <source>

                        <italic toggle="yes">J. Ophthalmol.</italic>
</source>
                    <year>2016</year>;<volume>2016</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>.
                    <pub-id pub-id-type="doi">10.1155/2016/7807596</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Keane</surname>
                            <given-names>PA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Karampelas</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sim</surname>
                            <given-names>DA</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Objective Measurement of Vitreous Inflammation Using Optical Coherence Tomography.</article-title>
                    <source>

                        <italic toggle="yes">Ophthalmology.</italic>
</source>
                    <year>2014</year>;<volume>121</volume>:<fpage>1706</fpage>&#x2013;<lpage>1714</lpage>.
                    <pub-id pub-id-type="pmid">24835759</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ophtha.2014.03.006</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4507470</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zarranz-Ventura</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Keane</surname>
                            <given-names>PA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sim</surname>
                            <given-names>DA</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Ophthalmol.</italic>
</source>
                    <year>2016</year>;<volume>161</volume>:<fpage>172</fpage>&#x2013;<lpage>180.e4</lpage>.
                    <pub-id pub-id-type="pmid">26476212</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2015.10.009</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zicarelli</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ometto</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Montesano</surname>
                            <given-names>G</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Objective Quantification of Posterior Segment Inflammation: Measuring Vitreous Cells and Haze Using Optical Coherence Tomography.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Ophthalmol.</italic>
</source>
                    <year>2023</year>;<volume>245</volume>:<fpage>134</fpage>&#x2013;<lpage>144</lpage>.
                    <pub-id pub-id-type="pmid">36084686</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2022.08.025</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Davis</surname>
                            <given-names>JL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Madow</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cornett</surname>
                            <given-names>J</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Scale for photographic grading of vitreous haze in uveitis.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Ophthalmol.</italic>
</source>
                    <year>2010</year>;<volume>150</volume>(<issue>5</issue>):<fpage>637</fpage>&#x2013;<lpage>641.e1</lpage>.
                    <pub-id pub-id-type="pmid">20719302</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2010.05.036</pub-id>
                    <pub-id pub-id-type="pmcid">PMC3220938</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Saito</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Barbazetto</surname>
                            <given-names>IA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Spaide</surname>
                            <given-names>RF</given-names>
                        </name>
</person-group>:
                    <article-title>Intravitreal cellular infiltrate imaged as punctate spots by spectral-domain optical coherence tomography in eyes with posterior segment inflammatory disease.</article-title>
                    <source>

                        <italic toggle="yes">Retina.</italic>
</source>
                    <year>2013</year>;<volume>33</volume>:<fpage>559</fpage>&#x2013;<lpage>565</lpage>.
                    <pub-id pub-id-type="pmid">23042101</pub-id>
                    <pub-id pub-id-type="doi">10.1097/IAE.0b013e31826710ea</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Song</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Liao</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>X</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Vitreous M2 Macrophage-Derived Microparticles Promote RPE Cell Proliferation and Migration in Traumatic Proliferative Vitreoretinopathy.</article-title>
                    <source>

                        <italic toggle="yes">Invest. Ophthalmol. Vis. Sci.</italic>
</source>
                    <year>2021</year>;<volume>62</volume>(<issue>12</issue>):<fpage>26</fpage>.
                    <pub-id pub-id-type="pmid">34554178</pub-id>
                    <pub-id pub-id-type="doi">10.1167/iovs.62.12.26</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8475283</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kita</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hata</surname>
                            <given-names>Y</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Arita</surname>
                            <given-names>R</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.</article-title>
                    <source>

                        <italic toggle="yes">Proc. Natl. Acad. Sci. U. S. A.</italic>
</source>
                    <year>2008</year>;<volume>105</volume>(<issue>45</issue>):<fpage>17504</fpage>&#x2013;<lpage>17509</lpage>.
                    <pub-id pub-id-type="pmid">18952846</pub-id>
                    <pub-id pub-id-type="doi">10.1073/pnas.0804054105</pub-id>
                    <pub-id pub-id-type="pmcid">PMC2582249</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hasanpour</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kenney</surname>
                            <given-names>MC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kuppermann</surname>
                            <given-names>BD</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Vitreal Concentrations of Vascular Endothelial Growth Factor in Patients with Rhegmatogenous Retinal Detachment.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Med.</italic>
</source>
                    <year>2023</year>;<volume>12</volume>(<issue>4</issue>):<fpage>1259</fpage>.
                    <pub-id pub-id-type="pmid">36835796</pub-id>
                    <pub-id pub-id-type="doi">10.3390/jcm12041259</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9961416</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hinton</surname>
                            <given-names>DR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>He</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jin</surname>
                            <given-names>ML</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy.</article-title>
                    <source>

                        <italic toggle="yes">Eye.</italic>
</source>
                    <year>2002</year>;<volume>16</volume>:<fpage>422</fpage>&#x2013;<lpage>428</lpage>.
                    <pub-id pub-id-type="pmid">12101449</pub-id>
                    <pub-id pub-id-type="doi">10.1038/sj.eye.6700190</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <label>19</label>
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Djatikusumo</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ardhia</surname>
                            <given-names>SH</given-names>
                        </name>
</person-group>:
                    <data-title>Characteristics of Proliferative Vitreoretinopathy, Uveitis, and Normal Eyes.</data-title>[Dataset].
                    <source>

                        <italic toggle="yes">figshare.</italic>
</source>
                    <year>2023</year>.
                    <pub-id pub-id-type="doi">10.6084/m9.figshare.22632715.v1</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <label>20</label>
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Djatikusumo</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hanna</surname>
                            <given-names>S</given-names>
                        </name>
</person-group>:
                    <data-title>Optical Coherence Tomography (OCT) Images of Proliferative Vitreoretinopathy, Uveitis, and Normal Eyes.</data-title>[Dataset].
                    <source>

                        <italic toggle="yes">Mendeley Data.</italic>
</source>
                    <year>2023</year>;<volume>V1</volume>.
                    <pub-id pub-id-type="doi">10.17632/hbr5pwk5w5.1</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <label>21</label>
                <mixed-citation publication-type="other">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Djatikusumo</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ardhia</surname>
                            <given-names>SH</given-names>
                        </name>
</person-group>:
Informed Consent - Comparison of VIT/RPE-Relative Intensity in PVR and Uveitis (Translated to English).
                    <italic toggle="yes">figshare. Media.</italic>
                    <year>2023</year>.
                    <pub-id pub-id-type="doi">10.6084/m9.figshare.22707988.v1</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report185981">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.146826.r185981</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Laude</surname>
                        <given-names>Augustinus</given-names>
                    </name>
                    <xref ref-type="aff" rid="r185981a1">1</xref>
                    <role>Referee</role>
                </contrib>
                <aff id="r185981a1">
                    <label>1</label>Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>26</day>
                <month>7</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Laude A</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport185981" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.133812.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The authors describe a novel method using optical coherence tomography to evaluate and compare the images as a biomarker of different diseases of the eye. The aim of their study was to compare the OCT marker (vitreous/RPE relative intensity) between eyes with PVR, Uveitis and normal.</p>
            <p> </p>
            <p> The title should be changed to reflect using OCT to evaluate and compare between different eye pathologies. The current title failed to mention the 'normal eyes' and should probably not include the term 'vitreous/retinal pigment epithelium relative intensity' (which is a technical term).</p>
            <p> </p>
            <p> The abstract background needs to make clear the aim of the study which is comparing the different eyes with different pathologies, and not as stated 'to analyse the severity of inflammation in PVR progression'.</p>
            <p> </p>
            <p> The power calculation was not well described and the authors instead chose to cite the paper by Keane, et al. This is not ideal and the author should describe in this paper their rationale for arriving at the sample size of '29 for the uveitis' group. If this was the case, I am assuming that they meant to have 29 eyes in each of the categories to be compared but in the paper, they have analysed 12, 16, 19 and 28 eyes. Therefore, this would significantly impact on the conclusions that can be drawn from their study. This limitation should be stated in the conclusion, not just for the PVR group but also for the uveitis groups.</p>
            <p> </p>
            <p> In the results segment, the authors stated that only 28 eyes of the uveitis group and 19 eyes of the PVR group met the criteria of good and readable OCT. However, it was not clear why this was the case, especially when the authors took steps to exclude many factors that could have led to a poor OCT capture (e.g. media opacification, vitreous haemorrhage, etc.). More could be described as to why the images were ungradable.</p>
            <p> </p>
            <p> More should be described about how the OCT images were processed and analysed. They mentioned in the 'Procedure' segment that the images were 'randomized'. I wasn't clear what this meant.</p>
            <p> </p>
            <p> There was a spelling error for 'syphillis' in Table 3 and also in the Results segment.</p>
            <p> </p>
            <p> Overall, the manuscript writing could be improved a little from the language perspective.&#x00a0;</p>
            <p> </p>
            <p> </p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>No</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Partly</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>medical retina and advanced optical imaging</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment10026-185981">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Djatikusumo</surname>
                            <given-names>Ari</given-names>
                        </name>
                        <aff>Ophthalmology, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, Indonesia</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>4</day>
                    <month>8</month>
                    <year>2023</year>
                </pub-date>
            </front-stub>
            <body>
                <p>We would like to thank you for agreeing to be our article reviewer. We appreciate your suggestions for revisions of our article. We would also like to address certain aspects regarding your review. 
                    <list list-type="order">
                        <list-item>
                            <p>Regarding the title of the article, the authors believe that the term 'vitreous/retinal pigment epithelium relative intensity' should be included in the title, as it serves as the article's primary focus. The article primarily discusses the comparison of 'vitreous/retinal pigment epithelium relative intensity' as an objective measurement of vitreous inflammation in cases of PVR and uveitis, with normal eyes only as reference standards.</p>
                        </list-item>
                        <list-item>
                            <p>We have changed the aim of the study in the abstract section to &#x201c;analyze the vitreous inflammation of PVR.&#x201d;</p>
                        </list-item>
                        <list-item>
                            <p>The power calculation was achieved based on the correlation coefficient. We cite the paper by Keane et al of a previous study comparing the VRI measurement and Nussenblatt scale as a reference standard for diagnosing uveitis. The sample size obtained was 29 eyes. The number of subjects in the RRD-PVR and normal eyes were adjusted based on the sample size obtained (29 eyes for each case). However, during image acquisition and measurement of VRI, only 19 RRD cases and 28 uveitis cases and were considered as good and readable images, described as both vitreous area and RPE captured in one image and a clear view or visible RPE. We also divided the uveitis subjects into intermediate-posterior uveitis and panuveitis, to determine the vitreous inflammation in different types of uveitis.</p>
                        </list-item>
                        <list-item>
                            <p>A total of 37 eyes with RRD-PVR have met the inclusion criteria. However, during the OCT image acquisition, 18 cases could not undergo VRI measurement due to a high retinal detachment, which made it infeasible to capture both the vitreous area and RPE in a single image. We will add and revise the result section.</p>
                        </list-item>
                        <list-item>
                            <p>The protocol for VRI measurement from the OCT images was described in the method section of &#x201c;Quantitative measurements of the vitreous Inflammation using ImageJ&#x201d;. In the article revision, we will incorporate figures demonstrating the process of obtaining VRI (Vitreous/Retinal Pigment Epithelium Relative Intensity) using ImageJ from the OCT images.</p>
                        </list-item>
                        <list-item>
                            <p>We have revised the spelling errors in our revised article.</p>
                        </list-item>
                    </list>
                </p>
            </body>
        </sub-article>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report185983">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.146826.r185983</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Ruamviboonsuk</surname>
                        <given-names>Paisan</given-names>
                    </name>
                    <xref ref-type="aff" rid="r185983a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-6114-6220</uri>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Limwattanayingyong</surname>
                        <given-names>Jiravut</given-names>
                    </name>
                    <xref ref-type="aff" rid="r185983a2">2</xref>
                    <role>Co-referee</role>
                </contrib>
                <aff id="r185983a1">
                    <label>1</label>Department of Ophthalmology, College of Medicine, Rajavithi Hospital,, Rangsit University, Lak Hok, Pathum Thani, Thailand</aff>
                <aff id="r185983a2">
                    <label>2</label>Department of Ophthalmology, College of Medicine, Rajavithi Hospital, Rangsit University, Lak Hok, Pathum Thani, Thailand</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>26</day>
                <month>7</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Ruamviboonsuk P and Limwattanayingyong J</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport185983" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.133812.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This is a small study about detecting vitreous haze using OCT images in patients with RRD and early PVR compared to patients with uveitis. The study had a small sample size though the size was estimated based on data from the previous study.</p>
            <p> </p>
            <p> The objective of this study is good since OCT device is ubiquitous. Early detection of PVR from OCT may have a role in managing RRD in encouraging sooner surgery. The results are convincing that patients with PVR had the highest vitreous haze compared to uveitis patients and normal. However, there are some limitations which have not yet been discussed.</p>
            <p> </p>
            <p> The authors are not yet clear on how they measured the vitreous/RPE-Relative Intensity (VRI). I understand that they took the measurement method from the previous study but it should be clear here as well. The best thing is to show the VRI with figures.&#x00a0;</p>
            <p> </p>
            <p> Another major limitation that should be discussed is no comparison between RRD with and without PVR. It may be possible that those cases without PVR may still have vitreous haze from vitreous detachment (PVD). It would be great if the comparison between RRD with and without PVR showed similar results as this study. The procedure of detecting vitreous haze in this study would be very useful if the authors could demonstrate that the detection of PVR using this procedure is also better than clinical examination.&#x00a0;</p>
            <p> </p>
            <p> It is great that there are OCT images of the cases showing vitreous haze from PVR, the two uveitis groups, and normal, available as underlying data. It would be great if the authors can list the value of VRI for each case.</p>
            <p> </p>
            <p> Normally RPE cells would drop down by gravity to present at the inferior part of the eye. However, the OCT images are only from the macula area. It would be great if there are clinical examinations documenting the inferior vitreous of these eyes. Is obtaining only macula OCT images would be a limitation of applying this procedure in clinical practice since vitreous haze/RPE cells may be present inferiorly? I saw that some OCT images with high retinal detachment might have a much smaller area of vitreous to measure the VRI. Would this also be a limitation on applying this procedure in clinical practice?&#x00a0;</p>
            <p> </p>
            <p> Another potential bias is how the authors controlled the measurement of VRI on OCT by the two graders. Were there any agreement measurements between the two of them?</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Yes</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>No source data required</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Yes</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>retinal imaging, AI, wet AMD and DR</p>
            <p>We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment10008-185983">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Djatikusumo</surname>
                            <given-names>Ari</given-names>
                        </name>
                        <aff>Ophthalmology, Rumah Sakit Dr Cipto Mangunkusumo, Central Jakarta, Jakarta, Indonesia</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>The authors declare that they have no conflict of interest.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>1</day>
                    <month>8</month>
                    <year>2023</year>
                </pub-date>
            </front-stub>
            <body>
                <p>We would like to thank you for agreeing to be our article reviewer. We appreciate your suggestions and revisions to improve our article. We would also like to address certain aspects regarding the review. 
                    <list list-type="order">
                        <list-item>
                            <p>The protocol for VRI measurement was described in the method section of &#x201c;Quantitative measurements of the vitreous Inflammation using ImageJ.&#x201d; In the article revision, we will incorporate figures demonstrating the process of obtaining VRI (Vitreous/Retinal Pigment Epithelium Relative Intensity) using ImageJ in the Method section.</p>
                        </list-item>
                        <list-item>
                            <p>In our inclusion criteria, we specifically enrolled patients with RRD and PVR, considering that PVR is correlated with vitreous inflammation and is a significant contributor to surgical failure in RRD repair. PVR grading through clinical examination is subjective and can vary between clinicians. Measuring VRI is expected to objectively provide vitreous inflammation, along with detecting PVR cases in RRD. We will add this issue in the Discussion section.</p>
                        </list-item>
                        <list-item>
                            <p>We have uploaded the value of VRI for each case in the underlying data (figshare:&#x00a0;
                                <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.22632715.v1">https://doi.org/10.6084/m9.figshare.22632715.v1</ext-link>)</p>
                        </list-item>
                        <list-item>
                            <p>We acknowledge that we did not obtain measurements of vitreous inflammation for the inferior vitreous. However, all patients were examined in the same position (seated position), ensuring that the location of the vitreous being examined was possibly consistent. We are also aware that in cases of RRD, there were cases with high retinal detachments, with a much smaller vitreous area to measure the VRI. However, these cases are inevitable and are commonly found. The results of high retinal detachments also consistently show higher VRI compared to uveitis or normal eyes.</p>
                        </list-item>
                        <list-item>
                            <p>The two graders performed the VRI measurements using the same protocol described in the method section. Each grader measured the VRI twice. The highest VRI value among the two graders was taken as the result of VRI for each case. We will provide a more detailed explanation in the method section.</p>
                        </list-item>
                    </list>
                </p>
            </body>
        </sub-article>
    </sub-article>
</article>
